Tyligand

About Tyligand

Tyligand Bioscience is a clinical-stage biotechnology company founded in May 2018, with its headquarters in Zhangjiang Medicine Valley, Shanghai. The founders include seasoned pharmaceutical executives and leading researchers in protein phosphatase. The founding team includes Tony Zhang, PhD, who serves as CEO, and Boyu Zhong, PhD, as President. Dr. Tony Zhang was previously a Senior Research Fellow at Eli Lilly and the founding Managing Director of the Lilly China R&D Center.

The company focuses on discovering and developing innovative small molecule drugs and their conjugates to treat cancers and autoimmune diseases, particularly targeting drug-resistant tumors. Its research leverages deep knowledge of tumorigenesis signal transduction pathways and the tumor microenvironment. Tyligand operates an integrated 45,000 sq. ft. facility that supports medicinal chemistry, biological testing, and clinical development. The company's business model is centered on creating a pipeline of proprietary medicines. Tyligand generates revenue through partnerships and aims for the eventual commercialization of its therapeutic products. The company has successfully raised capital through multiple funding rounds, including a Series A+ round in July 2023, to advance its clinical trials in the US and China.

Tyligand's pipeline includes several candidates in clinical-stage development. TSN084 is a multi-kinase inhibitor for treating AML, which has received orphan drug designation from the U.S. FDA. Another key asset is TSN222, a dual-acting tumor immune agonist (DATIA®). The company is also developing GQ1010, a TROP2 ADC with a potentially wider therapeutic window, and TSN1611, a selective KRAS G12D inhibitor.